The companies’ new effort would bypass traditional middlemen to cut the drug’s monthly cost from a list price of around $606 ...

The joint venture is launching a direct-to-consumer service of Eliquis after discussions with the Trump administration.

Bristol Myers Squibb Co. closed 26.69% short of its 52-week high of $63.33, which the company achieved on March 11th.

Bristol Myers Squibb Co. closed 25.25% below its 52-week high of $63.33, which the company reached on March 11th.

Bristol Myers and Pfizer will sell Eliquis directly to U.S. patients at a discounted rate with transparent pricing and ...

The program will provide direct shipping to patients across all 50 states and Puerto Rico, offering an additional, simplified option for accessing Eliquis and full transparency into the associated ...

Shares of Bristol Myers Squibb Co. slid 3.42% to $46.86 Friday, on what proved to be an all-around dismal trading session for ...

Morgan Stanley identified Bristol-Myers Squibb (NYSE:BMY) as a catalyst-driven idea ahead of a key data readout for Cobenfy in Alzheimer’s Disease Psychosis (ADP), expected in late third or early ...

The program is the latest example of pharmaceutical companies bypassing traditional drug distribution channels for people who ...

Pharmaceutical giants introduce an insurance-free pathway for top anticoagulant Eliquis, following similar direct-to-patient models from Eli Lilly and Novo Nordisk.

Taking a page from Eli Lilly and Novo Nordisk, who have launched online programs to sell their diabetes and obesity drugs ...

BofA cuts Bristol Myers' 2025 EPS and sales estimates slightly and flags medium-term pressure from generics, while ...